AssureSign Secures Significant Investment Funding from Recurring Capital Partners


The private eSignature firm plans to earmark its investor funding for expansion of its partnership division and product development.

AssureSign, a leading eSignature platform enabling organizations to provide branded signing experiences, today announced securing substantial investment funding from Recurring Capital Partners.

The private software company plans to invest heavily within its product and partnership arms. The firm plans to provide accelerated paths to partnership and additional options for existing partners. AssureSign President & CEO David Brinkman stated the company plans to develop and release a number of new off-the-shelf and pre-built integrations spanning the industry spectrum in 2020 and 2021.

“Securing this funding allows us to scale up projections for product and market growth in 2021,” said David Brinkman, President & CEO of AssureSign. “As enterprises continue to invest in digital transformation, AssureSign plans to meet the market’s call for innovation with dynamic integrations among preferred and industry-specific platforms.”

Read More: Will 5G Adoption Expose Businesses to Cyber Threats and Other Security Challenges?

AssureSign’s announcement of additional funding comes amid its continued upward trajectory. In recognition of this growth, Recurring Capital Partners, an investment firm specializing in flexible debt financing for technology-driven companies, has added AssureSign to its investment portfolio.

“AssureSign has a proven track record of driving growth through innovation in a very dynamic electronic signature market,” said Brian Henley, managing partner at Recurring Capital Partners. “We are excited to partner with David and his team with growth capital to accelerate and scale their product and partnership initiatives.”

In response to significant market share gains, AssureSign has recently scaled up its workforce, expanding its product engineering, customer success, operations, and sales divisions.